Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma

Authors

  • Michael Ryott,

    1. Department of Clinical Science, Intervention and Technology, Karolinska Institute and Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author
  • Linda Marklund,

    1. Department of Clinical Science, Intervention and Technology, Karolinska Institute and Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author
  • Darawalee Wangsa,

    1. Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Search for more papers by this author
  • Göran Elmberger,

    1. Department of Oncology-Pathology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author
  • Eva Munck-Wikland

    1. Department of Clinical Science, Intervention and Technology, Karolinska Institute and Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author

Michael Ryott, MD, Department of Clinical Science, Intervention and Technology, Karolinska Institute and Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, S-17176 Stockholm, Sweden. Tel: +46 8 517 76061, Fax: +46 8 517 74265, E-mail: michael.ryott@karolinska.se

Abstract

J Oral Pathol Med (2010) 40: 385–389

Background:  Cyclooxygenase-2 expression is associated with unfavorable outcome in various cancers, and evidence is accumulating that carcinogenesis possibly evolves from intracellular changes in response to induction of this enzyme. Today selective cyclooxygenase-2 inhibitors are being studied and used as complement in cancer treatment. This study examined the prognostic value of cyclooxygenase-2 expression in oral tongue squamous cell carcinoma (OTSCC).

Methods:  Expression of cyclooxygenase-2 was determined in biopsies from 76 stage matched patients with OTSCC by immunohistochemistry between January 2000 and December 2004 in Stockholm, Sweden. Additionally, twelve samples taken after pre-operative radiotherapy were investigated.

Results:  All OTSCC specimen expressed cyclooxygenase-2 by immunostaining. The cyclooxygenase-2 staining intensity increased significantly with more advanced stage (P = 0.020). Fifty percent of the surgical specimen showed a decrease in immunostaining post-radiation (P = 0.031). No association was found with survival.

Conclusion:  Cyclooxygenase-2 expression has limited prognostic value in OTSCC.

Ancillary